Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Expression of CEA, CA19-9, CA125, and EpCAM in pseudomyxoma peritonei.

Human pathology - 1 Aug 2016

Nummela Pirjo, Leinonen Hannele, Järvinen Petrus, Thiel Alexandra, Järvinen Heikki, Lepistö Anna, Ristimäki Ari

Abstract excerpt

Pseudomyxoma peritonei is a fatal clinical syndrome with mucinous tumor cells disseminated into peritoneal cavity and secreting abundant mucinous ascites. The serum tumor markers CEA, CA19-9, and CA125 are used to monitor pseudomyxoma peritonei remission, but their expression at tissue level has not been well characterized. Herein, we analyzed expression of these proteins and the adenocarcinoma marker EpCAM in 92...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biopsy
Share to CA-125 Antigen
Share to CA-19-9 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoembryonic Antigen

Share to Epithelial Cell Adhesion Molecule

Share to Fucosyltransferases

Share to Neoplasm Grading

Share to Peritoneal Neoplasms

Source

Identifiers

PMID: 27038681
DOI: 10.1016/j.humpath.2016.02.022

Genes

FUT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Expression of CEA, CA19-9, CA125, and EpCAM in pseudomyxoma peritonei.PMID 27038681Read ↗

Molecular profiles of high-grade and low-grade pseudomyxoma peritonei.Semantic proximity Read ↗

Pathological prognostic factors of pseudomyxoma peritonei: comprehensive clinicopathological analysis of 155 cases.Semantic proximity Read ↗

Appendix-derived Pseudomyxoma Peritonei (PMP): Molecular Profiling Toward Treatment of a Rare Malignancy.Semantic proximity Read ↗

Rare Occurrence of Pseudomyxoma Peritonei (PMP) Syndrome Arising from a Malignant Transformed Ovarian Primary Mature Cystic Teratoma Treated by Cytoreductive Surgery and HIPEC: A Case ReportSemantic proximity Read ↗

The mutational landscape and prognostic indicators of pseudomyxoma peritonei originating from the ovary.Semantic proximity Read ↗

Progress on immuno-microenvironment and immune-related therapies in patients with pseudomyxoma peritonei.Semantic proximity Read ↗

A case of Pseudomyxoma Peritonei of an unexpected origin.Semantic proximity Read ↗

Distinct cell states define the developmental trajectories of mucinous appendiceal neoplasms towards pseudomyxoma metastasesSemantic proximity Read ↗

Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry.Semantic proximity Read ↗

Pseudomyxoma Peritonei as a First Manifestation of KRAS-Mutated Urachal Mucinous Cystadenocarcinoma of the Bladder: A Case Report.Semantic proximity Read ↗

Exploring the peritoneal surface malignancy phenotype--a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models.Semantic proximity Read ↗

Targeted Genetic Sequencing Analysis of 223 Cases of Pseudomyxoma Peritonei Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Shows Survival Related to GNAS and KRAS Status.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.